蛋白质糖基化：免疫治疗的“新-旧”靶点。
Protein Glycosylation: "New-yet-Old" Target for Immunotherapy.
机构信息
Metabolic Programming, TUM School of Life Sciences Weihenstephan; ZIEL-Institute for Food and Health, Technical University of Munich (TUM), Freising, Germany.
Institute of Immunology, Christian-Albrechts-University Kiel & University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
出版信息
Clin Cancer Res. 2020 Nov 15;26(22):5778-5780. doi: 10.1158/1078-0432.CCR-20-3364. Epub 2020 Sep 21.
The use of checkpoint monotherapy in treating cancer has limited success. Post-translational modifications (PTM) of proteins such as glycosylation might have clinical implications due to distinct modifications found in diseases and its regulatory role in the immunometabolic gene expression. Such novel mechanistic targets hold great promise for combined immunotherapy..
在治疗癌症中使用检查点单药治疗的效果有限。蛋白质的翻译后修饰（PTM），如糖基化，由于在疾病中发现的独特修饰及其在免疫代谢基因表达中的调节作用，可能具有临床意义。这些新的机制靶点为联合免疫治疗提供了巨大的希望。
Zotero 插件